Sana Biotechnology, Inc. (SANA): Price and Financial Metrics

Sana Biotechnology, Inc. (SANA): $8.06

0.11 (+1.38%)

POWR Rating

Component Grades













Add SANA to Watchlist
Sign Up

Industry: Biotech


of 450

in industry

SANA Stock Price Chart Interactive Chart >

Price chart for SANA

SANA Price/Volume Stats

Current price $8.06 52-week high $44.60
Prev. close $7.95 52-week low $7.66
Day low $7.66 Volume 2,553,563
Day high $8.10 Avg. volume 1,081,805
50-day MA $15.01 Dividend yield N/A
200-day MA $19.60 Market Cap 1.52B

Sana Biotechnology, Inc. (SANA) Company Bio

Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.

SANA Latest News Stream

Event/Time News Detail
Loading, please wait...

SANA Latest Social Stream

Loading social stream, please wait...

View Full SANA Social Stream

Latest SANA News From Around the Web

Below are the latest news stories about Sana Biotechnology Inc that investors may wish to consider to help them evaluate SANA as an investment opportunity.

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Yahoo | January 27, 2022

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products,

Yahoo | January 11, 2022

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes o

Yahoo | January 11, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, and Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today jointly announced that the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial ri...

Benzinga | January 10, 2022

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Tuesday, January 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of

Yahoo | January 4, 2022

Read More 'SANA' Stories Here

SANA Price Returns

1-mo -47.63%
3-mo -61.14%
6-mo -50.52%
1-year N/A
3-year N/A
5-year N/A
YTD -47.93%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8636 seconds.